The opportunity to improve the Mangoral product and add patent protection rights add significant value to Ascelia Pharma’s Mangoral franchise. With the new patent, the protection rights are further strengthened until year 2040 in the US.
The new patent covers an effervescent tablet formulation of Mangoral, which makes it even easier for patients and health care professionals to use Mangoral. Plans for market authorization and launch of the 2nd generation Mangoral are under development.
“We are very pleased to have granted the patent for an improved formulation of Mangoral. This will further benefit the target patient population for Mangoral and demonstrates our long-term commitment to provide better imaging solutions for a patient population with poor alternatives today. The new US patent will add significant value and is a result of our successful life cycle management work and our focus on developing novel and better medicinal products for patients in need,” said Magnus Corfitzen, CEO of Ascelia Pharma.
For more information, please contact
Magnus Corfitzen, CEO
Tel: +46 735 179 118
Mikael Widell, IR & Communications Manager
Tel: +46 703 11 99 60
This information is such information as Ascelia Pharma AB (publ) is obliged to make public pursuant to the EU Market Abuse Regulation.The information was submitted for publication, through the agency of the contact person set out above, at 7.30 am CET on 15 December 2020.
About Ascelia Pharma
Ascelia Pharma is a biotech company focused on orphan oncology treatments. We develop and commercialize novel drugs that address unmet medical needs and have a clear development and market pathway. The company has two drug candidates – Mangoral and Oncoral – in clinical development. Ascelia Pharma has global headquarters in Malmö, Sweden, and is listed on Nasdaq Stockholm (ticker: ACE). For more information, please visit www.ascelia.com.
Mangoral (manganese chloride tetrahydrate) is a novel oral contrast agent for MR-imaging developed to improve the detection and visualization of focal liver lesions (including liver metastases and primary tumors) in patients with reduced kidney function. These patients are at risk of serious side effects from the currently available class of gadolinium-based contrast agents. Mangoral, which has been granted an Orphan Drug Designation by the US Food and Drug Administration (FDA), is currently in Phase 3 development, including the global multi-center SPARKLE study.
The Orphan Drug Designation in the US provides a minimum of 7 years of exclusivity after its marketing authorization. In the EU, a new product is granted 10 years of exclusivity after EMA marketing authorization.